Is This the Most Undervalued Biotech of 2013?

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

If you were looking for a hot sector to buy at the beginning of 2013, biotech was it. The iShares Nasdaq Biotechnology ETF (NASDAQ: IBB  ) has soared more than 56% this year with only a few weeks to go. With biotech sizzling, you might think it would be hard to find an undervalued stock in the pack. Actually, that task isn't too hard.

Of course, there's a difference between cheap and undervalued. For example, PDL BioPharma (NASDAQ: PDLI  ) looks really inexpensive. The problem, though, is that the company's revenue is on track to begin drying up quickly with patents for its primary products expiring at the end of 2014. PDL is cheap, but I wouldn't say the stock is really undervalued considering the uncertainty that lies ahead.

There is a biotech, however, that could very well deserve the title of most undervalued in 2013. Questcor Pharmaceuticals (UNKNOWN: QCOR.DL  ) trounced the high-flying iShares Biotech ETF, with shares doubling year to date. Even  with this major surge, Questcor sports a trailing price-to-earnings ratio of only 12. The company's forward P/E of below 8 looks even more attractive.

Looking back
To best understand why Questcor has done so well but is still so inexpensive, we need to look back over the past year. Investors were scared in February after the company reported fourth-quarter 2012 results that showed declining sales for Acthar in treating multiple sclerosis. Sales for the indication had consistently climbed every quarter for five years, so an 8% drop nearly seemed like a sign of the apocalypse.

Yet another seeming signal of doom came a couple of months or so later when Questcor announced its first-quarter results. This time around, it wasn't just the multiple sclerosis indication that was problematic. Total shipments for Acthar fell for the first quarter in years. However, Questcor suspected that seasonality was a factor as well as its launching of a new reimbursement support center.

That suspicion appeared to be validated in the second quarter. Questcor blew away all revenue and earnings expectations. Contribution from a new sales push for rheumatology helped significantly. CEO Don Bailey said that the rheumatology launch was the best for a therapeutic area in company history.

Those winning ways continued into the third quarter. Questcor yet again knocked the ball out of the park with record sales and earnings. But that's when fears resurfaced about another possible dark cloud on the horizon.

Back in 2012, Questcor revealed that the U.S. attorney's office for the Eastern District of Pennsylvania was investigating the company's promotional practices. In October of this year, it was reported that the U.S. attorney's office for the Southern District of New York and the Los Angeles office of the SEC were joining that investigation. Since then, shares have declined nearly 25%.

Looking ahead
Largely because of the concerns about this investigation, Questcor's valuation is one of the lowest among biotech stocks. There are likely also some latent worries that payers will cut back on reimbursement for Acthar, although that hasn't proven to be a serious issue for Questcor so far.

Biotech's big run in 2013 narrows the list of low valuation stocks considerably. Anika Therapeutics (NASDAQ: ANIK  ) looks inexpensive when you look at its P/E-to-growth, or PEG, ratio, which stands at a low 0.73. However, Anika isn't so attractive without factoring in growth potential. Its trailing P/E is 27.

Actually, from a PEG perspective, there are only a couple of biotech stocks in the same league as Questcor. PDL BioPharma's PEG of 0.33 is lower than Questcor's 0.40. However, we already noted the issues surrounding PDL. 

China Biologic Products (NASDAQ: CBPO  ) boasts a PEG of 0.45. That's just a little higher than Questcor's. But China Biologic's trailing P/E of 17 is considerably higher than Questcor's multiple. The company also only barely increased revenue in the last quarter, whereas Questcor grew year-over-year revenue by nearly 70% in the third quarter.

It remains to be seen what the outcome of the investigation into Questcor's marketing practices will be. That uncertainty could dampen the stock's prospects for a while. However, I suspect that Questcor will keep chugging along with impressive sales of Acthar, especially as it expands into new indications. My vote is for Questcor as the most undervalued biotech stock of the year.

Which stock could be the big winner for next year?
The market stormed out to huge gains across 2013, leaving investors on the sidelines burned. However, opportunistic investors can still find huge winners. The Motley Fool's chief investment officer has just hand-picked one such opportunity in our new report: "The Motley Fool's Top Stock for 2014." To find out which stock it is and read our in-depth report, simply click here. It's free!

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2765045, ~/Articles/ArticleHandler.aspx, 10/1/2016 1:31:05 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 4 hours ago Sponsored by:
DOW 18,308.15 164.70 0.91%
S&P 500 2,168.27 17.14 0.80%
NASD 5,312.00 42.85 0.81%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
QCOR.DL $0.00 Down +0.00 +0.00%
Questcor Pharmaceu… CAPS Rating: **
ANIK $47.85 Up +1.75 +3.80%
Anika Therapeutics CAPS Rating: ****
CBPO $124.48 Up +0.75 +0.61%
China Biologic Pro… CAPS Rating: **
IBB $289.46 Up +3.59 +1.26%
iShares NASDAQ Bio… CAPS Rating: ****
PDLI $3.35 Up +0.12 +3.72%
PDL BioPharma CAPS Rating: ***